侯凡;田显敏;王留利;徐丽媛;王海琳;

• 1:兰州大学第一临床医学院
• 2:陕西中医药大学附属医院呼吸科
• 3:甘肃省人民医院妇科

摘要(Abstract)：

卵巢癌因缺乏早期诊断方法,大多数患者确诊时已处于晚期。绝大多数患者对化疗的先天性和获得性耐药是卵巢癌成功治疗的主要障碍,同时表观遗传修饰也与卵巢癌的耐药性有关,其中DNA甲基化是目前研究最多的表观遗传修饰。利用表观遗传治疗的方法使肿瘤抑制基因再表达,从而恢复耐药卵巢癌细胞对化疗药物的敏感性。现对DNA甲基化与卵巢癌多药耐药、诊断及治疗的关系,以及去甲基化药物用于卵巢癌治疗方面的研究进展作一阐述。

关键词(KeyWords)： DNA甲基化;卵巢癌;耐药;表观遗传治疗

Abstract:

Keywords:

基金项目(Foundation): 甘肃省自然基金项目(18JR3RA052)

作者(Author): 侯凡;田显敏;王留利;徐丽媛;王海琳;

Email:

DOI: 10.13463/j.cnki.cczyy.2020.06.068

参考文献(References)：

• [1]FANG F,CARDENAS H,HUANG H,et al.Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs[J].Cancer Res,2018,78(3):631-644.
• [2]YAN B,YIN F,WANG Q I,et al.Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer[J].Oncol Lett,2016,12(1):157-166.
• [3]BORGHESE B,ZONDERVAN K T,ABRAO M S,et al.Recent insights on the genetics and epigenetics of endometriosis[J].Clin Genet,2017,91(2):254-264.
• [4]HASHIMOTO Y,ZUMWALT T J,GOEL A.DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer[J].Epigenomics,2016,8(5):685-703.
• [5]HERVOUET E,PEIXOTO P,DELAGE-MOURROUX R,et al.Specific or not specific recruitment of DNMTs for DNA methylation,an epigenetic dilemma[J].Clinical epigenetics,2018,10(1):17-18.
• [6]BERGAMINI A,PISANO C,DI NAPOLI M,et al.Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin[J].Gynecol Oncol,2017,144(1):72-76.
• [7]MA B.Optimal primary therapy of ovarian cancer.[J].Annals of Oncology,2016,27(1):i58-i62.
• [8]VAN JAARSVELD M T,VAN KUIJK P F,BOERSMA A W,et al.miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway[J].Mol Cancer,2015,14:196.
• [9]ZELLER C,DAI W,STEELE N L,et al.Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling[J].Oncogene,2012,31(42):4567-4576.
• [10]FLANAGAN J M,WILSON A,KOO C,et al.Platinum-based chemotherapy induces methylation changes in blood dna associated with overall survival in patients with ovarian cancer[J].Clin Cancer Res,2017,23(9):2213-2222.
• [11]李续博,姜广宇,董航.川芎嗪联合紫衫醇对HL-60细胞凋亡的影响[J].长春中医药大学学报,2018,34(6):44-48.
• [12]姜雪莲,姚逸临,罗斌,等.低剂量化疗联合中医药治疗肺癌[J].长春中医药大学学报,2018,32(2):381-383.
• [13]HA Y N,SUNG H Y,YANG S D,et al.Epigenetic modification of alpha-N-acetylgalactosaminidase enhances cisplatin resistance in ovarian cancer[J].Korean J Physiol Pharmacol,2018,22(1):43-51.
• [14]LIU D,ZHANG X X,LI M C,et al.C/EBPbeta enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation[J].Nat Commun,2018,9(1):1739.
• [15]DE LEON M,CARDENAS H,VIETH E,et al.Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer[J].Gynecologic Oncology,2016,142(3):539-547.
• [16]ZHANG X,FENG Y,WANG X Y,et al.The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer[J].Cell Death Dis,2018,9(2):93.
• [17]TOMAR T,ALKEMA N G,SCHREUDER L,et al.Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer[J].BMC Med,2017,15(1):116.
• [18]HUANG R,GU F,KIRMA N B,et al.Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers[J].Epigenetics,2013,8(6):624-634.
• [19]FANG F,MUNCK J,TANG J,et al.The novel,small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer[J].Clin Cancer Res,2014,20(24):6504-6516.
• [20]CATTO J W,ALCARAZ A,BJARTELL A S,et al.MicroRNA in prostate,bladder,and kidney cancer:a systematic review[J].Eur Urol,2011,59(5):671-681.
• [21]KUANG Y,LU F,GUO J,et al.Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo[J].OncoTargets and therapy,2017,10:3131-3144.
• [22]JIN P,SONG Y,YU G.The role of abnormal methylation of wnt5a gene promoter regions in human epithelial ovarian cancer:a clinical and experimental study[J].Anal Cell Pathol (Amst),2018,2018:1-9.
• [23]DU J,ZHANG L.Integrated analysis of DNA methylation and microRNA regulation of the lung adenocarcinoma transcriptome[J].Oncol Rep,2015,34(2):585-594.
• [24]ANDREW W,LANZI S,JADE M.READUS,et al.Abstract 1016:Combination low dose 5-azacytidine (AZA) and romidepsin (FK228) therapy re-sensitizes ovarian cancer cells to cisplatin[J].Can Res,2013,73(8 Supplement):1016.
• [25]FU S,HU W,IYER R,et al.Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent,azacitidine,in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer[J].Cancer,2011,117(8):1661-1669.
• [26]MASE S,SHINJO K,TOTANI H,et al.ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer[J].Cancer Sci,2019,110(3):1105-1116.
• [27]BENSON E A,SKAAR T C,LIU Y,et al.Carboplatin with decitabine therapy,in recurrent platinum resistant ovarian cancer,alters circulating mirnas concentrations:a pilot study[J].PLoS One,2015,10(10):e141279.
• [28]STEWART M L,TAMAYO P,WILSON A J,et al.KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine[J].Cancer Res,2015,75(14):2897-2906.
• [29]LIU J,ZHANG X,HUANG Y,et al.miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases[J].Oncol Lett,2019,17(2):1453-1460.